VolitionRx Announces Collaboration with Wales Cancer Bank

News provided by

Jan 09, 2013, 06:30 ET

NAMUR, Belgium, Jan. 9, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it will commence a large internal clinical study for its Nucleosomics^® diagnostic products this month. This trial is being undertaken in addition to its four ongoing external clinical trials. The trial will be carried out in Volition's laboratory on patient blood samples supplied by the Wales Cancer Bank (www.walescancerbank.com), which is based in Cardiff, in the United Kingdom.

Beginning late January, NuQ^® tests will be conducted on blood samples taken from more than 800 cancer patients by the Wales Cancer Bank as well as healthy control volunteers. The expected sample distribution is as follows:

Breast cancer: approx. 550 patients with a variety of subtypes, including invasive ductal carcinoma, invasive lobular and tubular carcinomas, and in-situ carcinoma ductal
Colorectal cancer: approx. 230 patients with a variety of subtypes, at various stages from Stage A to Stage D
Plus smaller numbers of patients with lung and pancreatic cancers.

The study follows a highly successful pilot study on 100 patient samples from the Wales Cancer Bank, (results of which were announced in December 2012), after which Volition was awarded scientific approval from the Bank for the number of patients needed for a full scale clinical trial.

Jake Micallef, Chief Scientific Officer of VolitionRx, says: "These larger studies follow successful completion of our own internal pilot studies. This is the next step in obtaining European market approval for Nucleosomics diagnostic tests (beginning with the patient numbers needed for breast and colorectal cancer), and establishing them in routine clinical use."

Professor Malcolm Mason, Director of the Wales Cancer Biobank, says: "We are delighted to be providing patient blood samples for Volition's cancer trial. Their technology shows promise and we were very happy with their initial results in the pilot study carried out in 2012. We look forward to seeing the results from this larger trial."

In addition to the trial announced today, Volition is currently undertaking four trials: three multi-cancer trials currently underway at Rheinische Friedrich-Wilhelms-Universitat Bonn, Germany (see announcement here); and a study into colorectal cancer at CHU-UCL Mont-Godinne Hospital, Belgium (see announcement here).

About VolitionRx
VolitionRx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.

VolitionRx's development activities are currently centered in Belgium with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.

You can find more information about VolitionRx at our website at www.volitionrx.com, on Twitter at www.twitter.com/volitionrx, LinkedIn at www.linkedin.com/company/1364072?trk=tyah or Facebook at www.facebook.com/volitionrx.

Safe Harbor Statement
Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.

SOURCE VolitionRx Limited